The correlation between intestinal microecology and the efficacy of chemotherapy
ZIWAREGULI Nur, FANG Ruo-xin，LIAO Zheng-kai
Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University / Hubei Key Laboratory of Tumor Biological Behaviors / Hubei Cancer Clinical Study Center, Wuhan 430071, Hubei, China
Abstract：There is a symbiotic or antagonistic relationship between human intestinal flora, and a unique intestinal microecosystem is formed. After a long period of co-evolution, intestinal flora and human body have formed a close symbiotic relationship, and participate in many important physiological activities of the human body. Therefore, maintaining the balance of intestinal flora is essential to human health. The formation of human intestinal flora structure depends on many factors, such as diet, sex, mode of delivery, host genetic characteristics, host lifestyle, disease occurrence and antibiotic exposure. Escherichia coli, bifidobacteria, Lactobacillus and Proteus are the main intestinal flora in healthy people. Under normal physiological conditions, these bacteria maintain a dynamic balance of species and quantity. They can not only protect intestinal epithelial cells, but also participate in the physiological processes of immunity, nutrition, biological antagonism, anti-aging and anti-cancer in the life activities of the host. Intestinal flora can inhibit the occurrence and development of tumors and regulate inflammation by activating anti-tumor cytokines, regulating intestinal microenvironment and maintaining genomic stability. Moreover, the complete intestinal flora is also conducive to the development of anti-cancer drugs. Intestinal flora can affect the efficacy and toxicity of chemotherapy through flora translocation, immune regulation, metabolism, enzymatic degradation, diversity reduction and microecological changes. At the same time, chemotherapy can significantly affect the composition of intestinal flora, destroy the balance of intestinal microecology, and aggravate the discomfort of patients. More and more evidences show that intestinal bacteria can affect the efficacy or toxicity of chemotherapy, and that intestinal microecology may improve the efficacy and reduce toxicity of chemotherapy. This article reviews the relationship between intestinal flora and the efficacy and side effects of chemotherapy.
孜瓦热古丽·努尔，方若欣，廖正凯. 肠道微生态与化疗疗效的相关性[J]. 肿瘤代谢与营养电子杂志, 2019, 6(2): 161-166.
ZIWAREGULI Nur, FANG Ruo-xin，LIAO Zheng-kai. The correlation between intestinal microecology and the efficacy of chemotherapy. Electron J Metab Nutr Cancer, 2019, 6(2): 161-166.
1.Boulangé CL, Neves AL, Chilloux J, et al. Impact of the gut microbiota on inflammation, obesity, and metabolic disease. Genome Med. 2016;8(1):1-12.
2.Hollister EB, Riehle K, Luna RA, et al. Structure and function of the healthy pre-adolescent pediatric gut microbiome. Microbiome. 2015;3(1):36.
3.Lin A, Bik EM, Costello EK, et al. Distinct distal gut microbiome diversity and composition in healthy children from Bangladesh and the United States. PLoS One. 2013;8(1):e53838.
4.张宁，李菲，李玲，等.肠道菌群与多囊卵巢综合征关系的研究进展. 国际妇产科学杂志. 2018;45(1):101-105.
5.Jandhyala SM. Role of the normal gut microbiota. World J Gastroentero. 2015;21(29):8787.
6.De Santis S, Cavalcanti E, Mastronardi M, et al. Nutritional keys for intestinal barrier modulation. Front Immunol. 2015;6(2):1-15.
7.Roy S, Trinchieri G. Microbiota: a key orchestrator of cancer therapy. Nat Rev Cancer. 2017;17(5):271-285.
8.Dominguez-Bello MG, Costello EK, Contreras M, et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proceedings of the National Academy of Sciences. 2010;107(26):11971-11975.
9.Jost T, Lacroix C, Braegger C, et al. Assessment of bacterial diversity in breast milk using culture-dependent and culture-independent approaches. Brit J Nutr. 2013;110(7):1253-1262.
10.Bezirtzoglou E, Tsiotsias A, Welling GW. Microbiota profile in feces of breast- and formula-fed newborns by using fluorescence in situ hybridization (FISH). Anaerobe. 2011;17(6):478-482.
11.Lewis JD, Chen EZ, Baldassano RN, et al. Inflammation, antibiotics, and diet as environmental stressors of the gut microbiome in pediatric Crohns disease. Cell Host Microbe. 2017;22(2):247.
12.Leonard MM, Camhi S, Huedo-Medina TB, et al. Celiac disease genomic, environmental, microbiome, and metabolomic (CDGEMM) study design: approach to the future of personalized prevention of celiac disease. Nutrients.2015;7(11):9325-9336.
13.Dabrowska K, Witkiewicz W. Correlations of host genetics and gut microbiome composition. Front Microbiol. 2016;7:1357.
14.Turpin W, Espin-Garcia O, Xu W, et al. Association of host genome with intestinal microbial composition in a large healthy cohort. Nat Genet. 2016;48(11):1413-1417.
15.Yatsunenko T, Rey FE, Manary MJ, et al. Human gut microbiome viewed across age and geography. Nature. 2012;486(7402):222-227.
16.David LA, Maurice CF, Carmody RN, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014;505(7484):559-563.
17.Xu Z, Knight R. Dietary effects on human gut microbiome diversity. Br J Nutr. 2015;113 Suppl:S1-S5.
18.Maier L, Pruteanu M, Kuhn M, et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018;555(7698):623-628.
19.Zitvogel L, Ayyoub M, Routy B, et al. Microbiome and anticancer immunosurveillance. Cell. 2016;165(2):276-287.
20.Joukar F, Mavaddati S, Mansour-Ghanaei F, et al. Gut microbiota as a positive potential therapeutic factor in carcinogenesis: an overview of microbiota-targeted therapy. J Gastrointest Cancer. 2019.
DOI: 10.1007/s12029-019-00237-6.
21.黎源，吴疆. 肠道细菌移位的研究进展. 世界华人消化杂志. 2015;23(6):38-943.
22.Schiavoni G, Sistigu A, Valentini M, et al. Cyclophosphamide synergizes with type Ⅰ interferons through systemic dendritic cell reactivation and Induction of immunogenic tumor apoptosis. Cancer Res. 2011;71(3):768-778.
23.Ghiringhelli F, Larmonier N, Schmitt E, et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol. 2004;34(2):336-344.
24.Viaud S, Flament C, Zoubir M, et al. Cyclophosphamide induces differentiation of Th17 cells in cancer patients. Cancer Res. 2011;71(3):661-665.
25.Viaud S, Saccheri F, Mignot G, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science. 2013;342(6161):971-976.
26.Alexander JL, Wilson ID, Teare J, et al. Gut microbiota modulation of chemotherapy efficacy and toxicity. Nat Rev Gastro Hepat. 2017;14(6):356-365.
27.Schirmer M, Smeekens SP, Vlamakis H, et al. Linking the human gut microbiome to inflammatory cytokine production capacity. Cell. 2016;167(4):1125-1136.
28.Maroun JA, Anthony LB, Blais N, et al. Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea. Curr Oncol. 2007;14(1):13-20.
29.Jacobs JP, Braun J. Immune and genetic gardening of the intestinal microbiome. Febs Lett. 2014;588(22):4102-4111.
30.Zitvogel L, Lorenzo G, Sophie V, et al. Cancer and the gut microbiota: An unexpected link. Science Translational Medicine. 2015;7(271):271.
31.Agus A, Denizot J, Thévenot J, et al. Western diet induces a shift in microbiota composition enhancing susceptibility to adherent-invasive E. coli infection and intestinal inflammation. Sci Rep-Uk. 2016;6(4):19032.
32.Pope JL, Tomkovich S, Yang Y, et al. Microbiota as a mediator of cancer progression and therapy. Transl Res. 2017;179:139-154.
33.Rossini A, Rumio C, Sfondrini L, et al. Influence of antibiotic treatment on breast carcinoma development in proto-neu transgenic mice. Cancer Res. 2006;66(12):6219-6224.
34.Alka B, Yashwant K. Cellular and molecular mechanisms in cancer immune escape: a comprehensive review. Expert Rev Clin Immu. 2014;10(1):41-62.
35.Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
36.Domagala-Kulawik J. The role of the immune system in non-small cell lung carcinoma and potential for therapeutic intervention. Transl Lung Cancer Res. 2015;4(2):177-190.
37.Pardoll JRBA. Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer. Cancer Immunol Res. 2013;1(2):85-91.
38.Stewart CA, Müller W, Trinchieri G. Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation. J Clin Invest. 2013;123(11):4859-4874.
39.Pang Y, Gara SK, Achyut BR, et al. TGF-b signaling in myeloid cells is required for tumor metastasis. Cancer Discov. 2013;3(8):936-951.
40.AXQ, Hankui CB, Xiaofeng WA, et al. Interleukin-17 acts as double-edged sword in anti-tumor immunity and tumorigenesis. Cytokine. 2017;89(6):34-44.
41.Vetizou M, Pitt JM, Daillere R, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350(6264):1079-1084.
42.Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015;350(6264):1084-1089.
43.Geis AL, Fan H, WuX, et al. Regulatory T-cell response to enterotoxigenic bacteroides fragilis colonization triggers IL17-dependent colon carcinogenesis. Cancer Discov. 2015;5(10):1098-1109.
44.Nosho K. Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer. World J Gastroentero. 2016;22(2):557.
45.Rouits E, Charasson V, Petain A, et al. Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients. Br J Cancer. 2008;99(8):1239-1245.
46.Slatter JG, Schaaf LJ, Sams JP, et al. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of ［(14)C］CPT-11 in cancer patients. Drug Metab Dispos. 2000;28(4):423-433.
47.Saliba F, Hagipantelli R, Misset JL, et al. Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment. J Clin Oncol. 1998;16(8):2745-2751.
48.Kurita A, Kado S, Matsumoto T, et al. Streptomycin alleviates irinotecan-induced delayed-onset diarrhea in rats by a mechanism other than inhibition of β-glucuronidase activity in intestinal lumen. Cancer Chemoth Pharm. 2011;67(1):201-213.
49.Dubin K, Callahan MK, Ren B, et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun. 2016;7(2):10391.
50.Huang S, Li JY, Wu J, et al. Mycoplasma infections and different human carcinomas. World J Gastroenterol. 2001;7(2):266-269.
51.Bronckaers A, Balzarini J, Liekens S. The cytostatic activity of pyrimidine nucleosides is strongly modulated by Mycoplasma hyorhinis infection: Implications for cancer therapy. Biochem Pharmacol. 2008;76(2):188-197.
52.VandeVoorde J, Sabuncuoglu S, Noppen S, et al. Nucleoside-catabolizing enzymes in mycoplasma-infected tumor cell cultures compromise the cytostatic activity of the anticancer drug gemcitabine. J Biol Chem. 2014;289(19):13054-13065.
53.Scott TA, Quintaneiro LM, Norvaisas P, et al. Host-microbe co-metabolism dictates cancer drug efficacy in celegans. Cell. 2017;169(3):442-456.
54.Fijlstra M, Ferdous M, Koning AM, et al. Substantial decreases in the number and diversity of microbiota during chemotherapy-induced gastrointestinal mucositis in a rat model. Support Care Cancer. 2015;23(6):1513-1522.
55.Forsgrd RA, Marrachelli VG, Korpela K, et al. Chemotherapy-induced gastrointestinal toxicity is associated with changes in serum and urine metabolome and fecal microbiota in male Sprague-Dawley rats. Cancer Chemoth Pharm. 2017;80(2):317-332.
56.Wrzosek L, Miquel S, Noordine ML, et al. Bacteroides thetaiotaomicron and Faecalibacterium prausnitzii influence the production of mucus glycans and the development of goblet cells in the colonic epithelium of a gnotobiotic model rodent. Bmc Biol. 2013;11:61.
57.Hong BY, Sobue T, Choquette L, et al. Chemotherapy-induced oral mucositis is associated with detrimental bacterial dysbiosis. Microbiome. 2019;7(1):66.
58.Gatti L, Zunino F. Overview of tumor cell chemoresistance mechanisms. Methods Mol Med. 2005;111:127-148.
59.Panebianco C, Andriulli A, Pazienza V. Pharmacomicrobiomics: exploi-ting the drug-microbiota interactions in anticancer therapies. Microbiome. 2018;6(1):92.
60.Touchefeu Y, Montassier E, Nieman K, et al. Systematic review: the role of the gut microbiota in chemotherapy- or radiation-induced gastrointestinal mucositis - current evidence and potential clinical applications. Aliment Pharmacol Ther. 2014;40(5):409-421.
61.van Vliet MJ, Harmsen HJ, de Bont ES, et al. The role of intestinal microbiota in the development and severity of chemotherapy-induced mucositis. PLoS Pathog. 2010;6(5):e1000879.
62.Stringer AM, Al-Dasooqi N, Bowen JM, et al. Biomarkers of chemotherapy-induced diarrhoea: a clinical study of intestinal microbiome alterations, inflammation and circulating matrix metalloproteinases. Support Care Cancer. 2013;21(7):1843-1852.
63.Wallace BD, Wang H, Lane KT, et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science. 2010;330(6005):831-835.
64.Xu Y. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol. 2002;13(12):1841-1851.
65.Bowen JM, Stringer AM, Gibson RJ, et al. VSL#3 probiotic treatment reduces chemotherapy-induced diarrhea and weight loss. Cancer Biol Ther. 2007;6(9):1449-1454.
66.Iida N, Dzutsev A, Stewart CA, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science. 2013;342(6161):967-970.
